September 29, 2026

September 29, 2026September 29, 2026

Medical laboratory professional holding a blood sample tube for liquid biopsy analysis, with additional blood samples, laboratory equipment, and a diagnostic monitor in the background.

Liquid Biopsy for Cancer: How It Works and Why It Matters

Liquid biopsy for cancer: What it is, how it works, and why it matters in India

A blood test that’s changing how cancer is detected, monitored, and treated

This page is for informational purposes only and does not replace medical advice. Please consult Dr. Aditya Sarin or a qualified oncologist to understand whether liquid biopsy testing is appropriate for your specific case. As of 2026, this reflects current clinical guidance.

For decades, confirming and characterizing a cancer meant a needle, an endoscope, or surgery, whatever it took to get a physical piece of the tumor. Liquid biopsy changes that equation for many patients, at least in part, by pulling the same kind of genetic information out of a simple blood draw. It isn’t a replacement for everything a tissue biopsy does, but it’s become a genuinely useful tool in several specific situations.

What is a liquid biopsy?

According to the National Cancer Institute, a liquid biopsy analyzes bits of tumor material, mainly DNA, but also RNA, proteins, or whole cells, found in bodily fluids such as blood. The most widely used version looks for circulating tumor DNA, or ctDNA, tiny fragments of DNA that tumor cells shed into the bloodstream as part of their normal life cycle.

This is different from a tissue biopsy, which requires physically removing a piece of the tumor, sometimes through a large needle, an endoscope, or open surgery. According to MD Anderson Cancer Center, ctDNA fragments are distinguishable from ordinary cell-free DNA released by healthy, dying cells, mainly by their shorter length, which is part of what makes the test technically possible.

How liquid biopsy testing works

Once a blood sample is drawn, laboratory technology analyzes it for the presence and quantity of ctDNA, along with any specific genetic mutations it carries. Because tumors constantly release DNA as their cells divide and die, a growing tumor generally sheds more ctDNA, and a shrinking one sheds less, which is part of what allows the test to track a cancer’s behavior over time rather than just confirm its presence once.

There are two broad approaches. Testing for specific known mutations is useful once a cancer type is established and doctors want to check for one particular genetic change, while broader genomic profiling screens ctDNA more comprehensively across many genes at once, often used when the exact treatment-relevant mutation isn’t yet known.

Liquid biopsy vs tissue biopsy: What each one actually tells you

Tissue biopsy remains what the National Cancer Institute calls the gold standard for diagnosing cancer and examining its cells directly under a microscope, and it’s still generally required to confirm a cancer diagnosis in the first place. Liquid biopsy is better suited to different jobs: identifying mutations that guide targeted drug selection, tracking whether ctDNA levels are falling or rising during treatment, and in some cases picking up early signs that a cancer is coming back, sometimes months before it would be visible on a scan.

The two aren’t interchangeable, and a negative liquid biopsy result doesn’t rule out cancer the way a negative tissue biopsy might. If a liquid biopsy doesn’t detect a mutation that a tissue biopsy would confirm, regulators, including the FDA, have recommended falling back on tissue testing rather than treating the blood test result as final.

Why non-invasive cancer testing matters

The appeal of liquid biopsy is fairly intuitive once you consider what tissue biopsies actually involve. A blood draw is safe, inexpensive, and easy to repeat, while a tissue biopsy carries real procedural risk and generally isn’t something a patient can undergo every few weeks to check on treatment progress. This matters especially for monitoring: since ctDNA can be tracked repeatedly over the course of treatment, it offers a way to watch how a cancer is responding without the burden of repeated invasive procedures.

That said, the technology still has real, acknowledged limitations. According to a 2024 update from the National Cancer Institute, one of liquid biopsy’s biggest technical challenges is simply that tumors, particularly small or shrinking ones, often don’t release enough ctDNA into the bloodstream for current tests to reliably detect. Researchers are actively working to improve this sensitivity, but for now, a negative liquid biopsy doesn’t always mean there’s nothing to find.

Why liquid biopsy matters in India

Precision oncology in India increasingly depends on identifying specific genetic mutations to match patients with targeted therapies, something we’ve covered across several cancer types on this site, from EGFR and ALK testing in lung cancer to BRCA testing in breast and ovarian cancer. Liquid biopsy offers a way to get at this information without always requiring a fresh tissue sample, which matters in situations where re-biopsying a tumor is difficult, risky, or simply not something a patient wants to go through again.

Access to this technology in India is expanding through major cancer centers, though it remains a specialized test used selectively rather than a routine part of every cancer workup. Whether it’s the right tool for a specific situation depends on the cancer type, the question being asked, mutation status, and whether it’s for detection or monitoring, and should be discussed directly with an oncologist.

Note. Recommend confirming with Dr. Sarin which specific liquid biopsy panels or indications his practice currently uses, so the page reflects his actual approach accurately.

The takeaway

Liquid biopsy is a genuinely useful addition to cancer care, particularly for guiding targeted therapy and monitoring treatment response, but it works alongside tissue biopsy and imaging rather than replacing them outright. Understanding what the test can and can’t tell you helps set the right expectations if your doctor recommends one.

If you have questions about whether liquid biopsy testing is relevant to your diagnosis or treatment plan, book a consultation with Dr Aditya Sarin at Sir Ganga Ram Hospital, New Delhi.

References

National Cancer Institute: Liquid Biopsy: Using Tumor DNA in Blood to Aid Cancer Care.
MD Anderson Cancer Centre: Liquid Biopsies: Understanding ctDNA and Circulating Tumor Cells.
National Cancer Institute: Pump Up the Volume: “Priming Agents” May Improve Cancer Liquid Biopsies.

September 29, 2026September 29, 2026

Middle-aged Indian man seated in a hospital chair having a focused conversation with a male doctor in a softly lit cancer-care setting, with an infusion pump in the background.

Dr. Aditya Sarin Blog

Immunotherapy Side Effects: What Patients Should Know

Immunotherapy Side Effects: What Patients Need to Know Before Starting Treatment

Why immunotherapy side effects look different from chemo and what to watch for

This page is for informational purposes only and does not replace medical advice. Please consult Dr Aditya Sarin or a qualified oncologist about your specific treatment plan and what side effects to expect. As of 2026, this reflects current clinical guidance.

If you’re about to start immunotherapy, you’ve probably already heard it described as “gentler” than chemotherapy. In many ways, that’s fair; many patients tolerate it well. But immunotherapy side effects work through a completely different mechanism than chemo side effects, and that difference matters. They can show up later than you’d expect, in places you wouldn’t necessarily connect to a cancer drug, and they need to be reported quickly rather than waited out. Here’s what’s actually going on in your body, what’s common, and what needs urgent attention.

Why immunotherapy side effects are different from chemotherapy

Chemotherapy damages fast-growing cells throughout the body, which is why it causes things like hair loss and nausea. Immunotherapy works through an entirely different mechanism. According to the National Cancer Institute, immunotherapy helps your immune system detect and destroy cancer cells more effectively, and many side effects happen because that revved-up immune system also attacks healthy cells and tissue. In other words, the same process that helps immunotherapy fight cancer also causes side effects, which is part of why oncologists can’t simply turn the treatment “down” the way they might adjust a chemo dose.

This immune overactivation is why immunotherapy side effects are officially called immune-related adverse events (irAEs) rather than just “side effects.” They resemble autoimmune conditions because, functionally, that’s close to what’s happening: your immune system, no longer held in check, starts treating parts of your own body as a threat.

Common early side effects

According to the American Cancer Society, the most frequently reported immunotherapy side effects include:

Fatigue
Skin changes, including rash or itching
Flu-like symptoms such as fever, chills, and muscle aches
Stomach issues like nausea, vomiting, or diarrhoea
Soreness, redness, or swelling at the injection or infusion site

Most of these are mild and show up early in treatment. They’re also, importantly, not a sign the treatment isn’t working, and they’re not automatically a sign it is either. Report them to your care team regardless, since the same symptom can range from a minor nuisance to the first sign of something that needs medication.

Immune-related adverse events: What to know about the more serious ones

Beyond the common early symptoms, immunotherapy can affect specific organs in ways that need closer monitoring. Per guidance summarised by the National Comprehensive Cancer Network and echoed across major cancer centres, the organs most commonly affected include:

Lungs (pneumonitis): New or worsening cough, shortness of breath, chest pain
Gut (colitis): Diarrhoea, blood in stool, severe abdominal pain
Liver (hepatitis): Yellowing of the skin or eyes, dark urine, right-sided abdominal pain, unusual fatigue
Endocrine glands (thyroiditis, adrenal insufficiency): Unexplained weight change, feeling unusually cold or hot, extreme tiredness, dizziness
Skin: Rash, blistering, painful sores

Thyroid problems are worth knowing about specifically. Immunotherapy-related thyroid damage is often permanent once it happens, meaning patients may need thyroid hormone replacement medication for life, according to oncology nurse practitioners who monitor these effects closely. It’s manageable, but it doesn’t reverse on its own once treatment ends.

Most immune-related adverse events, according to the Cancer Council, tend to appear several weeks or months after starting treatment rather than immediately, and in rare cases can appear even after treatment has finished. That delay is part of why ongoing monitoring matters throughout, not just at the start.

Immunotherapy and fatigue

Fatigue shows up with immunotherapy for different reasons than it does with chemo. It’s not usually tied to anaemia or bone marrow suppression the way chemo fatigue often is. Instead, it can be a general immune-system response, or, in some cases, an early sign of an endocrine problem like thyroid or adrenal involvement, both of which commonly cause tiredness.

That distinction matters practically. If fatigue during immunotherapy is new, worsening, or paired with other changes, weight shifts, feeling unusually cold, or dizziness, it’s worth flagging to your oncologist rather than assuming it’s simply treatment-related tiredness. A quick blood test can usually tell the difference.

When immunotherapy side effects need urgent attention

Immune-related adverse events can escalate faster than people expect, which is why prompt reporting matters more here than with most cancer treatments. Symptoms that need a same-day call to your oncology team, or emergency care if you can’t reach them, include:

Severe or worsening shortness of breath, or new chest pain.
Severe diarrhoea, or blood in your stool.
Yellowing of the skin or eyes.
Confusion, severe headache, neck stiffness, or vision changes.
Severe muscle weakness or new numbness.
A fever that doesn’t settle, especially alongside any of the above.

Even mild versions of these symptoms are worth mentioning early. Immune-related adverse events are far easier to manage when caught before they progress, and most are reversible with prompt treatment, typically corticosteroids to calm the immune response, when addressed quickly.

How your medical oncologist manages immunotherapy side effects

Because irAEs can appear late and affect almost any organ, monitoring during immunotherapy is often more structured than during chemo. A medical oncologist like Dr Aditya Sarin typically orders regular bloodwork to catch early thyroid, liver, or kidney changes before symptoms appear, asks about new or unusual symptoms at every visit, and has a clear plan for grading severity and stepping in with steroids or other treatment when something crosses the line from mild to concerning. This kind of active surveillance is part of what makes immunotherapy safer in practice than it might sound on paper.

The takeaway

Immunotherapy side effects work differently from chemo side effects, and understanding that difference, especially the delayed timing and the wide range of organs that can be affected, helps you know what’s worth reporting and when. If you’re considering immunotherapy or already partway through treatment, book a consultation with Dr Aditya Sarin to talk through what to expect and how your specific treatment plan will be monitored.